Elena Ridloff, a member of Kymera Therapeutics' board of directors, reported the sale of 12,000 shares of Kymera Therapeutics common stock (NASDAQ: KYMR) across two days at prices that produced proceeds in excess of $1 million.
According to a Form 4 filed with the U.S. Securities and Exchange Commission, Ridloff sold 7,400 shares on March 31, 2026, and an additional 4,600 shares on April 1, 2026. The sales were executed at transaction prices ranging from $85.1946 to $86.05 per share, resulting in total consideration above $1 million.
On the same two dates, Ridloff exercised stock options to acquire 12,000 shares of Kymera common stock at an exercise price of $14.18 per share. The exercise carried an aggregate cost of $170,160.
Separately, Kymera Therapeutics announced that data from the KT-621 BroADen Phase 1b clinical trial in patients with atopic dermatitis will be presented at the American Academy of Dermatology 2026 Annual Meeting. The company said the KT-621 data presentation is scheduled for March 28, 2026, in Denver, Colorado.
Following the release of Kymera's fourth-quarter and full-year 2025 financial results, several investment analysts adjusted price targets on the stock while maintaining upbeat ratings. Stephens increased its price target to $100 and kept an Overweight rating. Morgan Stanley cut its target to $123 but also maintained an Overweight rating. RBC Capital raised its price target to $108 and retained an Outperform rating, citing ongoing phase II development of KT-621 in atopic dermatitis and asthma.
Analysts referenced the continued advancement of Kymera's degrader pipeline and the market opportunity in type 2 diseases. They also noted that the company may experience a quieter period in the coming year as it focuses resources on ongoing trials.
This report compiles the transaction details disclosed by the insider filing and the company and summarizes subsequent analyst commentary as reported. The filing, option exercise amounts, presentation date, and analyst price-target changes are presented as disclosed.